Atherosclerotic vascular disease of the carotid artery
Conditions
Interventions
Participants will be randomized to either treatment with mycophenolate mofetil (MMF) or placebo.
Sponsors
Academic Medical Center
Amsterdam, the Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: Consecutive patients with carotid artery stenosis (>70% diameter stenosis on angiography or ultrasonography) with ipsilateral transient ischemic attack (TIA) who are planned to undergo carotid endarterectomy (CEA) will be included and treated for a minimum of three weeks prior to surgery. These patients will be recruited at the outpatient department of Vascular Surgery.
Exclusion criteria
Exclusion criteria: Patients who are unable to tolerate MMF treatment, who withdraw their consent or those with any other medical condition or laboratory abnormality which in the opinion of the principal investigator could affect subject safety, preclude evaluation of response, or render unlikely that the patient would complete the study, are excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| After 3 weeks of treatment: Immunostaining for: CD3, CD4, CD8, CD40L, CD69, CD86. | — |
Secondary
| Measure | Time frame |
|---|---|
| After 3 weeks of treatment: Immunostaining for endothelial, plaque composition and stability markers | — |
Contacts
Public ContactSander Leuven, van
Academic Medical Center (AMC), Department of Vascular Medicine, room F4-159.2, P.O. Box 22660
Outcome results
None listed